The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV

• Status: Recruiting
• Trial end date: 2029-05-30
• Target enrollment: 0
• Participant gender: All

Summary

To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xijing Hospital
• Treatments: Palonosetron

Criteria

Inclusion Criteria:

• For patients with malignant tumors who can accept chemotherapy, the disease type is not limited. The specific chemotherapy scheme is the chemotherapy scheme with moderate risk of vomiting (for the risk level of vomiting, refer to the 2019 CSCO anti-tumor treatment related nausea and vomiting prevention and treatment guidelines);

• 18-75 years old, KPS score ≥ 70, and the expected survival time is more than 3 months;

• Before treatment, ECG, blood routine test, liver and kidney functions and electrolytes were basically normal;

• All patients signed the informed consent form

Exclusion Criteria:

• Patients with chemotherapy contraindications, patients allergic to 5-HT3RA, pregnant women and lactating women;

• People with digestive tract obstruction; Patients with serious heart disease, liver and kidney disease and metabolic disorder; Patients suffering from epilepsy or using psychotropic and sedative drugs;

• Used antiemetic drugs or chemicals within 24 hours.Those who have vomited before treatment may have brain metastasis, intracranial hypertension, gastrointestinal obstruction, psychological abnormalities, etc.Patients with factors causing nausea and vomiting.